Company profile: NuCana
1.1 - Company Overview
Company description
- Provider of ProTide phosphoramidate chemistry technology transforming widely prescribed nucleoside analog chemotherapies into more effective and safer cancer medicines. Programs include NUC-3373 (5-FU) for colorectal and other solid tumors, NUC-7738 (cordycepin) for solid tumors and melanoma, and Acelarin/NUC-1031 (gemcitabine) for biliary tract, pancreatic, and ovarian cancers.
Products and services
- NUC-3373: A ProTide-transformed 5-FU engineered to improve efficacy, safety, and administration challenges in treating colorectal cancer and other solid tumors
- NUC-7738: A phosphoramidate-enabled transformation of 3'-deoxyadenosine (cordycepin) engineered to overcome breakdown, transportation, and activation limitations, showing potent anti-cancer activity in solid tumors and melanoma
- ProTide Technology: A phosphoramidate-engineered platform that transforms widely prescribed chemotherapy nucleoside analogs into more effective, safer medicines by overcoming cancer resistance mechanisms and other limitations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NuCana
Light Chain Bio
HQ: Switzerland
Website
- Description: Provider of research and development of novel multi-specific antibodies that rely on their light chain for their function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Light Chain Bio company profile →
Biodesix
HQ: United States
Website
- Description: Provider of data-driven lung cancer diagnostic testing and biopharma services, offering the IQLung Treatment Guidance strategy—GeneStrat targeted, GeneStrat NGS genomic, and VeriStrat proteomic tests—to inform NSCLC treatment decisions, plus Nodify Lung testing (Nodify CDT and Nodify XL2) to assess malignancy risk in lung nodules and support early detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biodesix company profile →
MTM Laboratories
HQ: Germany
Website
- Description: Provider of ISO 9001 and 13485 certified in-vitro diagnostics for early detection and diagnosis of cervical and other cancers; headquartered in Heidelberg, Germany, with subsidiaries in the United States, France, Italy and Spain; markets proprietary CINtec Histology Kit and CINtec.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MTM Laboratories company profile →
Traws Pharma
HQ: United States
Website
- Description: Provider of clinical-stage small molecule oral therapies, including investigational inhibitors for COVID-19 (TRX01/ratutrelvir) and pandemic influenza (TRX100/tivoxavir marboxil), and narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor in trials for refractory endometrial and metastatic breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Traws Pharma company profile →
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NuCana
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NuCana
2.2 - Growth funds investing in similar companies to NuCana
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NuCana
4.2 - Public trading comparable groups for NuCana
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →